Related Experiment Video
Updated: Jun 19, 2026
06:15
Protocol and Guidelines for Point-of-Care Lung Ultrasound in Diagnosing Neonatal Pulmonary Diseases Based on International Expert Consensus
Published on: March 6, 2019
Update on pediatric lung allocation in the United States
1Department of Pediatrics, Washington University, St. Louis, MO 63110, USA. sweet@kids.wustl.edu
Pediatric Transplantation
|October 17, 2009
Summary
A new lung allocation system (LAS) was implemented in 2005 to improve survival for patients awaiting lung transplants. Early outcomes show the LAS benefits pediatric lung transplant candidates, with future changes planned.
Area of Science:
- Thoracic Surgery
- Transplant Immunology
- Public Health Policy
Background:
- The Lung Allocation Score (LAS) system was implemented in May 2005 in the United States.
- The LAS aims to reduce waiting list mortality and maximize one-year post-transplant survival.
- Previous lung allocation methods did not adequately address the specific needs of all patient groups.
Purpose of the Study:
- To evaluate the considerations for pediatric candidates in the LAS development.
- To analyze early outcomes of the LAS, focusing on pediatric lung transplant recipients.
- To discuss future modifications and their potential impact on pediatric lung transplantation.
Main Methods:
- Analysis of LAS implementation data from May 2005 onwards.
- Comparison of pre-LAS and post-LAS outcomes for pediatric lung transplant candidates.
- Review of policy documents and outcome data related to lung allocation.
Main Results:
- The LAS incorporates models of waiting list mortality and transplant survival benefit.
- Early observations indicate positive impacts on pediatric lung transplant candidates.
- Specific adjustments were made to accommodate pediatric considerations within the LAS framework.
Conclusions:
- The LAS represents a significant advancement in deceased donor lung allocation for adolescents and adults.
- The system demonstrates a commitment to improving outcomes for pediatric lung transplant recipients.
- Ongoing evaluation and future adjustments are crucial for optimizing the LAS in pediatric lung transplantation.
Related Concept Videos
01:17Pharmacokinetics in Pediatric Patients: Drug Distribution
Drug distribution in the pediatric population exhibits unique challenges and considerations due to the physiological differences between children, particularly neonates and infants, and adults. A crucial aspect of pediatric pharmacology is understanding how these differences impact the pharmacokinetics of various drugs, necessitating age-specific dosing strategies to ensure efficacy and safety.Neonates and infants have a higher total body water content, ~75%–90% of their body weight, compared...
01:29Drug Dosing: Infants and Children
Pediatric patient dosages diverge from adults due to disparities in body surface area, total body water, and extracellular fluid per kilogram of body weight. The dosing regimen considers the variations in pharmacokinetics and pharmacology across distinct age groups, encompassing preterm newborns, infants, young children, older children, and adolescents. Calculation of pediatric patient doses is predicated on determining body surface area, which exhibits a superior correlation with the child's...
01:26Pharmacokinetics in Pediatric Patients: Drug Excretion
In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...